Titus Gary 4
4 · SCICLONE PHARMACEUTICALS INC · Filed Jun 18, 2012
Insider Transaction Report
Form 4
Titus Gary
Senior VP Finance & CFO
Transactions
- Sale
Common Stock
2012-06-14$7.05/sh−15,029$105,954→ 37,095 total - Exercise/Conversion
Common Stock
2012-06-15$0.95/sh+36,954$35,106→ 74,049 total - Purchase
Common Stock
2012-05-31$3.84/sh+261$1,003→ 37,095 total - Exercise/Conversion
Common Stock
2012-06-14$0.95/sh+15,029$14,278→ 52,124 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2012-06-15−36,954→ 98,017 totalExercise: $0.95Exp: 2018-12-16→ Common Stock (36,954 underlying) - Exercise/Conversion
Incentive Stock Option (right to buy)
2012-06-15−29,624→ 68,393 totalExercise: $0.95Exp: 2018-12-16→ Common Stock (29,624 underlying) - Exercise/Conversion
Common Stock
2012-06-15$0.95/sh+29,624$28,143→ 66,719 total - Exercise/Conversion
Incentive Stock Option (right to buy)
2012-06-14−15,029→ 134,971 totalExercise: $0.95Exp: 2018-12-16→ Common Stock (15,029 underlying) - Sale
Common Stock
2012-06-15$6.99/sh−36,954$258,308→ 37,095 total - Sale
Common Stock
2012-06-15$6.99/sh−29,624$207,072→ 37,095 total
Footnotes (4)
- [F1]Purchased under the Issuer's Employee Stock Purchase Plan on May 31, 2012.
- [F2]Granted under the Issuer's 2005 Equity Incentive Plan.
- [F3]25% of such shares vest one year from the date of grant and 2.0833% vests each month thereafter, provided that Reporting Person continues to be employed by the Issuer.
- [F4]Provided Reporting Person remains employed by the Issuer, the Option will vest based on the achievement of certain performance targets on or prior to December 31, 2010, with 25,000 shares respectively vesting upon attainment of each of three specified goals. If these targets are not achieved on or before December 31, 2010, the Option will not vest and will terminate at that time.